OpGen, Inc. Announces Participation in New European Union Clinical Microbiology Research Consortium
2/23/2012 6:38:09 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--OpGen, Inc., a whole-genome analysis company developing and commercializing a complete suite of break-through products and services based on its proprietary Whole Genome Mapping technology, announced today the company’s participation in the European Union’s Patho-NGen-Trace research program. This multi-year project aims to bring Next Generation Sequencing (NGS) from a specialized basic research method to a standard routine tool for medical and bio-industrial microbiology applications, providing faster pathogen identification with whole sequence genetic characterization. OpGen’s Whole Genome Mapping technology will be used with NGS to generate more accurate sequences of the model pathogens, and to characterize genetic markers for drug-resistance, virulence and whole genome evolution that may not be detected by NGS alone.
comments powered by